(Q87809056)

English

Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial

scientific article published on 24 January 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24795251%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24795251%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

1 reference

ChEBI release 2020-05-28

1 reference

based on heuristic

inferred from title

type 2 diabetes

0 references

placebo-controlled trial

1 reference

based on heuristic

inferred from title

chronic renal insufficiency

1 reference

based on heuristic

inferred from title

author name string

Anthony H Barnett

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24795251%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Ambrish Mithal

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24795251%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Jenny Manassie

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24795251%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Russell Jones

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24795251%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Henning Rattunde

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24795251%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Hans J Woerle

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24795251%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Uli C Broedl

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24795251%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

EMPA-REG RENAL trial investigators

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24795251%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

publication date

24 January 2014

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24795251%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

The Lancet: Diabetes & Endocrinology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24795251%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24795251%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24795251%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

369-384

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24795251%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Type 2 diabetes mellitus and renal impairment in a large outpatient electronic medical records database: rates of diagnosis and antihyperglycemic medication dose adjustment

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970208-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Chronic kidney disease in the type 2 diabetic patients: prevalence and associated variables in a random sample of 2642 patients of a Mediterranean area.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970208-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970208-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970208-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970208-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970208-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Standards of medical care in diabetes--2012

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970208-0

7 January 2021

based on heuristic

inferred from DOI database lookup

KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970208-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970208-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970208-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970208-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970208-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970208-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970208-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970208-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970208-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970208-0

7 January 2021

based on heuristic

inferred from DOI database lookup

KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970208-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970208-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The GFR and GFR decline cannot be accurately estimated in type 2 diabetics

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970208-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Monitoring kidney function in type 2 diabetic patients with incipient and overt diabetic nephropathy.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970208-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S2213-8587(13)70208-0

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24795251%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24795251%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q87809056&oldid=1516071587"